EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Paulina Biniecka iD, Saki Matsumoto iD, Axel Belotti, Jessie Joussot, Jian Fei Bai iD, Somi Reddy Majjigapu iD, Paul Thoueille iD, Dany Spaggiari, Vincent Desfontaine, Francesco Piacente iD, Santina Bruzzone iD, Michele Cea iD und 5 weitere

Molecules · 2023

DOI: 10.3390/molecules28041897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Paulina Biniecka und 16 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausa…. Hauptthemen laut MEDLINE: Enzyme Inhibitors, Hematologic Neoplasms, Nicotinamide Phosphoribosyltransferase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Dr Dubois-Ferrière Dinu Lipatti, Fondation Emma Muschamp, Seventh Framework Program PANACREAS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting cancer cells that are highly dependent on the nicotinamide adenine dinucleotide (NAD+) metabolite is a promising therapeutic strategy. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme catalyzing NAD+ production. Despite the high efficacy of several developed NAMPT inhibitors (i.e., FK866 (APO866)) in preclinical studies, their clinical activity was proven to be limited. Here, we report the synthesis of new NAMPT Inhibitors, JJ08, FEI191 and FEI199, which exhibit a broad anticancer activity in vitro. Results show that these compounds are potent NAMPT inhibitors that deplete NAD+ and NADP(H) after 24 h of drug treatment, followed by an increase in reactive oxygen species (ROS) accumulation. The latter event leads to ATP loss and mitochondrial depolarization with induction of apoptosis and necrosis. Supplementation with exogenous NAD+ precursors or catalase (ROS scavenger) abrogates the cell death induced by the new compounds. Finally, in vivo administration of the new NAMPT inhibitors in a mouse xenograft model of human Burkitt lymphoma delays tumor growth and significantly prolongs mouse survival. The most promising results are collected with JJ08, which completely eradicates tumor growth. Collectively, our findings demonstrate the efficient anticancer activity of the new NAMPT inhibitor JJ08 and highlight a strong interest for further evaluation of this compound in hematological malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enzyme InhibitorsHematologic NeoplasmsNicotinamide PhosphoribosyltransferaseAnimalsHumansMiceCell Line, TumorCytokinesNADReactive Oxygen Species

Stichwörter der Autor:innen

ATPNADNAMPT inhibitorPK studiesanticancerapoptosisleukemialymphomamultiple myelomaoxidative stressvitamin B3

Substanzen

CytokinesEnzyme InhibitorsNADNicotinamide PhosphoribosyltransferaseReactive Oxygen Species

Autor:innen und Institutionen

  • Central Laboratory of Hematology, Department of Medical Laboratory and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Laboratory of Glycochemistry and Asymmetric Synthesis, Swiss Federal Institute of Technology (EPFL), 1015 Lausanne, Switzerland.
  • Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Department of Experimental Medicine, Section of Biochemistry, University of Genoa, 16132 Genoa, Italy.
  • Department of Internal Medicine and Medical Specialties, University of Genoa, 16132 Genoa, Italy.
  • Ospedale Policlinico San Martino IRCCS, Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.

ORCID-Profile: Paulina Biniecka, Saki Matsumoto, Jian Fei Bai, Somi Reddy Majjigapu, Paul Thoueille, Francesco Piacente, Santina Bruzzone, Michele Cea, Pierre Vogel, Aimable Nahimana

Förderung

  • Fondation Dr Dubois-Ferrière Dinu Lipatti
  • Fondation Emma Muschamp
  • Seventh Framework Program PANACREAS
  • European FP7 project INTEGRATA

Zitieren

APA

Biniecka, P., Matsumoto, S., Belotti, A., Joussot, J., Bai, J. F., Majjigapu, S. R., Thoueille, P., Spaggiari, D., Desfontaine, V., Piacente, F., Bruzzone, S., Cea, M., Decosterd, L. A., Vogel, P., Nencioni, A., Duchosal, M. A., & Nahimana, A. (2023). Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. Molecules. https://doi.org/10.3390/molecules28041897

Vancouver

Biniecka P, Matsumoto S, Belotti A, Joussot J, Bai JF, Majjigapu SR, et al. Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. Molecules. 2023. doi:10.3390/molecules28041897

BibTeX
@article{Biniecka2023,
  author = {Biniecka, Paulina and Matsumoto, Saki and Belotti, Axel and Joussot, Jessie and Bai, Jian Fei and Majjigapu, Somi Reddy and Thoueille, Paul and Spaggiari, Dany and Desfontaine, Vincent and Piacente, Francesco and Bruzzone, Santina and Cea, Michele and Decosterd, Laurent A and Vogel, Pierre and Nencioni, Alessio and Duchosal, Michel A and Nahimana, Aimable},
  title = {Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28041897}
}
Kostenlos starten →